Beyond 2 years, CABG with flow assessment was associated with a higher risk for new coronary angiography and new ...

European shares hit a seven-week high on Friday lifted by healthcare stocks and strong results from Cartier-owner Richemont, ...

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline: Basel Saturday, May 17, 2025, 11:00 Hrs [IST] Novartis will present data from ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

Hospital groups are celebrating a federal judge’s initial ruling against pharmaceutical makers who contended a government ...

Moreover, previous studies have suggested that more conservative options can be successfully used for low-risk, early-stage cervical cancer. The SHAPE trial, for example, showed that simple ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

The region-wide STOXX 600 index rose 0.4% by 0710 GMT, set for its fifth consecutive weekly advance. Other local bourses also ...

Coherus BioSciences, Inc.’s CHRS share price has surged by 6.25%, which has investors questioning if this is right time to sell.

Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, ...